Chemotherapy remains the cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. The colorectal cancer treatment landscape has shifted toward personalized treatment, with tumor sidedness and various biomarkers playing an important role in treatment selection. The colorectal cancer market is changing, largely fueled by the entry of immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo) and BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi). Both Opdivo (with or without Yervoy) and Keytruda are approved for advanced or recurrent MSI-H / dMMR colorectal cancer. Keytruda is also approved as first-line treatment for MSI-H / dMMR metastatic colorectal cancer. Braftovi in combination with an EGFR inhibitor (Erbitux) is now available for use as subsequent therapy for metastatic colorectal cancer patients with a BRAF V600E mutation. Given the intense Phase II/III pipeline activity, we anticipate the approval of several new therapies for colorectal cancer during the forecast period, such as the VEGFR inhibitor fruquintinib (Hutchmed) and KRAS inhibitor adagrasib (Mirati Therapeutics). These therapies will contribute to the robust market growth anticipated over the 2021-2031 forecast period.
How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers, and how will drug-treatment rates change over the 2021-2031 forecast period?
What are interviewed experts’ views on current and emerging late-phase therapies, and what strategies are companies pursuing to secure uptake and share in the colorectal cancer market?
Which are the most promising emerging therapies in the late-phase pipeline that are poised to launch for colorectal cancer, and what unmet needs do they address? What uptake and patient shares can late-phase pipeline agents currently in development for colorectal cancer expect to secure?
What are the key drivers and constraints in the colorectal cancer market, and how will they change in the major markets over the forecast period?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Expectations for the market authorization and sales opportunity for Favezelimab / Keytruda fixed-dose combination in colorectal cancer
Analysis of the clinical development program for Opdualag
Key ongoing clinical trials of Opdualag in the treatment of colorectal cancer
Expert insight: Opdualag for the treatment of colorectal cancer
Expectations for market authorization and sales opportunity for Opdualag in colorectal cancer
Key results from select clinical trials investigating OncoVAX for the treatment of colorectal cancer
Analysis of the clinical development program for OncoVAX
Key ongoing clinical trials of OncoVAX in the treatment of colorectal cancer
Expert insight: OncoVAX
Expectations for market authorization and sales opportunity for OncoVAX in colorectal cancer
Analysis of the clinical development program for Sym-004
Key ongoing clinical trials of Sym-004 in the treatment of colorectal cancer
Expert insight: Sym-004
Expectations for market authorization and sales opportunity for Sym-004 in colorectal cancer
Early-phase pipeline analysis
Select compounds in early-phase development for colorectal cancer
Access & reimbursement overview
Region-specific reimbursement practices
Key market access considerations in colorectal cancer: United States
General reimbursement environment: United States
Key market access considerations in colorectal cancer: EU5
General reimbursement environment: EU5
Key market access considerations in colorectal cancer: Japan
General reimbursement environment: Japan
Colorectal cancer bibliography
Laura Ramos Garcia, M.Sc., Ph.D., is an analyst on the Oncology team at Clarivate. During her training as a Ph.D., she gained in-depth knowledge in the field of cell death and inflammation. As a postdoctoral researcher, she worked on an emerging type of small molecule, PROTAC, that allows targeted protein degradation. She obtained her master of science degree in molecular medicine at Imperial College London and her doctorate in cancer biology at the Institute of Cancer Research (University of London).